About REGENXBIO Inc.

REGENXBIO Inc., founded in 2009, has established itself as a leader in AAV gene therapy with both a proprietary product pipeline and a platform licensing business. The company's NAV Technology Platform includes novel AAV vectors that can deliver genes to specific tissues and organs. RGNX stock price reflects the company's dual value drivers of internal product development and technology licensing revenues.

Led by CEO Kenneth Mills, REGENXBIO has advanced multiple gene therapy programs while building a strong licensing business with major pharmaceutical partners. The management team combines gene therapy expertise with business development acumen to maximize platform value. Leadership's strategic focus on both product development and platform partnerships has created multiple paths to value creation influencing RGNX stock price potential.

REGENXBIO operates through two synergistic businesses: developing its own gene therapy product candidates for retinal diseases, neurodegenerative diseases, and metabolic disorders, while licensing its NAV Technology Platform to partners developing their own gene therapies. The company benefits from licensing revenues and milestones that fund internal development while maintaining significant upside from its proprietary programs. With gene therapy poised for significant growth, REGENXBIO's validated platform technology, multiple clinical programs, and strong partnership revenues, RGNX offers investors diversified exposure to the gene therapy revolution with both near-term revenues and long-term product potential.